Paul Edward Kelly, Director at RELMADA THERAPEUTICS, INC. (RLMD), sold 4,085 shares at $3543.00 ($6.5M) on 2021-01-22, disclosed to the SEC on 2021-01-26.
Scheduled sale ($6.5M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.18 | 300 | $11K | 0.2% |
| 2 | $3543.00 | 1,800 | $6.4M | 98.7% |
| 3 | $35.27 | 1,300 | $46K | 0.7% |
| 4 | $35.16 | 685 | $24K | 0.4% |
| Total | $1580.95 avg | 4,085 | $6.5M | 100% |
| Filing → |
| RLMD | BUY | 2024-09-11 | $65K | — | Filing → |
| RLMD | SELL | 2022-04-05 | $300K | — | Filing → |
| RLMD | SELL | 2021-03-11 | $357K | — | Filing → |